PP_1170x120_10-25-21

FlexPen

Novo Nordisk breaks ground on diabetes medicine facility

Novo Nordisk breaks ground on diabetes medicine facility

CLAYTON, N.C. — Novo Nordisk Inc. has broken ground on a new $1.8 billion diabetes medicine production facility in Clayton, N.C. The 833,000-square-f00t Clayton facility will make active pharmaceutical ingredients (API) for a range of Novo Nordisk’s current and future GLP-1 and insulin medicines. Plans call for the facility to become fully operational in 2020